<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143465</url>
  </required_header>
  <id_info>
    <org_study_id>H-15019063</org_study_id>
    <nct_id>NCT03143465</nct_id>
  </id_info>
  <brief_title>Pharmacologically Triggered Migraine Without Aura and Neuroimaging</brief_title>
  <official_title>MR-Angiografi (MRA) og MR-Spektroskopi (MRS) Hos Raske forsøgspersoner og Patienter Med migræne Uden Aura Provokeret Med Calcitonin Gen-relateret Peptid (CGRP) og Sildenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and&#xD;
      ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental&#xD;
      questions of migraine, which remains to be elucidated, is the mechanism behind the generation&#xD;
      of migraine attacks.&#xD;
&#xD;
      The investigators will use calcitonin gene-related peptide (CGRP) and sildenafil as&#xD;
      pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to&#xD;
      investigate the attack initiating pathophysiology.&#xD;
&#xD;
      Both substances have previously been administered to healthy participants and migraine&#xD;
      without aura patients, inducing headache and migraine-like-attacks.&#xD;
&#xD;
      The investigators hope to contribute with novelty to the current understanding of the&#xD;
      migraine pathophysiology and development of more efficient treatment of migraine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CGRP and sildenafil induced headache and MRI changes</measure>
    <time_frame>0- 12h</time_frame>
    <description>CGRP and sildenafil induced headache and MRI changes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>CGRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin Gene-Related Peptide</intervention_name>
    <arm_group_label>CGRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 50 years&#xD;
&#xD;
          -  Weight: 50-100 kg&#xD;
&#xD;
          -  Diagnosis of migraine without aura (patient group only)&#xD;
&#xD;
          -  Attacks of migraine without aura at least once every second month (patient group only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inconsistent laterality of headache&#xD;
&#xD;
          -  History or family history of migraine (healthy subject group only)&#xD;
&#xD;
          -  Tension-type headache more than one day per month on average (healthy subject group&#xD;
             only)&#xD;
&#xD;
          -  Tension-type headache to such a degree that the episodic migraine diagnosis is no&#xD;
             longer fulfilled&#xD;
&#xD;
          -  Any other primary headache disorder&#xD;
&#xD;
          -  Daily intake of medication (apart from oral contraceptives)&#xD;
&#xD;
          -  Intake of any medication less than 4 half-lives before study start&#xD;
&#xD;
          -  Daily smoking&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Headache 48 h prior to study day&#xD;
&#xD;
          -  Hypertension on the study day (systolic BP&gt;150 mmHg or diastolic BP&gt; 100 mmHg)&#xD;
&#xD;
          -  Hypotension on the study day (systolic BP&lt;90 mmHg or diastolic BP&lt;50 mmHg)&#xD;
&#xD;
          -  History of any cardiovascular disease including cerebrovascular disease&#xD;
&#xD;
          -  Any disorder, that is deemed ineligible for participation by the study physicians&#xD;
&#xD;
          -  Contraindications of MRI&#xD;
&#xD;
          -  No use of safe contraception (women of fertile age only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center, University Hospital</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Samaira Younis</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

